Dong-A ST Co., Ltd. (170900.KS)
KSE · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩34,900 (+2.95%) as of
Key statistics
- Market cap
- 336.39B
- Forward P/E
- 10.23
- Dividend yield
- 2.06%
- 52-week range
- 31,600.00 – 56,380.95
- Beta
- 0.42
- Revenue (TTM)
- 860.94B
- Profit margin
- 1.01%
- Analyst target
- ₩56,952.38
- Volume
- 33.42k
About Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seoul, South Korea
- Employees
- 1,649
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.